A COMPARATIVE STUDY OF DORZOLAMIDE + TIMOLOL VS. BRIMONIDINE + TIMOLOL FIXED COMBINATION THERAPY IN THE MANAGEMENT OF PRIMARY OPEN ANGLE GLAUCOMA
Abstract
Background: To compare the efficiency of dorzolamide + timolol fixed combination vs. the Brimonidine + timolol fixed combination in the management of primary open-angle glaucoma Materials and methods: A prospective study conducted over a period of 6 months with a total of 69 patients having primary open angle glaucoma (POAG) who completed a follow up of 6 months at a tertiary care hospital. Detailed history of the patient was obtained and patients were assessed for best corrected visual acuity, base line IOP with Goldmann applanation tonometer and detailed anterior and posterior segment examination. They were categorized into two groups according to the combinations prescribed by the ophthalmologist as follow: group 1-dorzolamide+timolol and group 2-brimonidine+timolol. A follow up evaluation of each patient was done at 1, 3 and 6 months after baseline visit. Results: During our study the baseline IOP for dorzolamide + timolol group was 25.7 ±4.25 mm Hg and for brimonidine + timolol group was 26.3 ±5.86 mm Hg. During 6 months treatment, the mean reduction in IOP was 7.83 mm Hg (29.4%) in dorzolamide + timolol group and 9.39 mm Hg (35.6%) in brimonidine + timolol group. Conclusion: Our study showed that brimonidine + timolol combination has superiority over dorzolamide + timolol to reduce the IOP in newly diagnosed patients with POAG The value of IOP reduction in our study in brimonidine + timolol group was 9.39 mm Hg (35.6%) and 7.83 mm Hg (29.4%) in dorzolamide + timolol group.
KEYWORDS: Primary open angle glaucoma, brimonidine, timolol, dorzolamide.
Downloads
Downloads
Published
Issue
Section
License
The journal allows the author(s) to hold the copyright without restrictions and will retain publishing rights without restrictions.
The submitted papers are assumed to contain no proprietary material unprotected by patent or patent application; responsibility for technical content and for protection of proprietary material rests solely with the author(s) and their organizations and is not the responsibility of the journal. The main (first/corresponding) author is responsible for ensuring that the article has been seen and approved by all the other authors. It is the responsibility of the author to obtain all necessary copyright release permissions for the use of any copyrighted materials in the manuscript prior to the submission.
What are my rights as an author?
It is important to check the policy for the journal to which you are submitting or publishing to establish your rights as
Author. Journal's standard policies allow the following re-use rights:
- The journal allows the author(s) to hold the copyright without restrictions.
- The journal allows the author(s) to obtain publishing rights without restrictions.
- You may do whatever you wish with the version of the article you submitted to the journal.
- Once the article has been accepted for publication, you may post the accepted version of the article on your own personal website, your department's website or the repository of your institution without any restrictions.
- You may not post the accepted version of the article in any repository other than those listed above (i.e. you may not deposit in the repository of another institution or a subject-matter repository) until 12 months after publication of the article in the journal.
- You may use the published article for your own teaching needs or to supply on an individual basis to research colleagues, provided that such supply is not for commercial purposes.